Short-term therapy with simvastatin reduces inflammatory mediators and heart inflammation during the acute phase of experimental Chagas disease

Memorias do Instituto Oswaldo Cruz

Volumn 107, Issue 4, 2012, Pages 513-521

  Silva, Rafael Rodrigues ^a   Shrestha Bajracharya, Deena ^a   Almeida Leite, Camila Megale ^a,b   Leite, Rômulo ^a   Bahia, Maria Terezinha ^a   Talvani, Andre ^a  

^a FEDERAL UNIVERSITY OF OURO PRETO   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Chagas cardiomyopathy; Chemokinesinflammation; Simvastatin; Trypanosoma cruzi

Indexed keywords

AUTACOID; GAMMA INTERFERON; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA;

ACUTE DISEASE; ANIMAL; ARTICLE; BLOOD; C57BL MOUSE; CHAGAS DISEASE; DISEASE MODEL; FIBROSIS; MALE; MOUSE; MYOCARDITIS; PATHOLOGY; TIME;

ACUTE DISEASE; ANIMALS; CHAGAS CARDIOMYOPATHY; DISEASE MODELS, ANIMAL; FIBROSIS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION MEDIATORS; INTERFERON-GAMMA; MALE; MICE; MICE, INBRED C57BL; MYOCARDITIS; SIMVASTATIN; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA; MURINAE; MUS; TRYPANOSOMA CRUZI;

EID: 84862283921     PISSN: 00740276     EISSN: 16788060     Source Type: Journal    
DOI: 10.1590/S0074-02762012000400012     Document Type: Article

References (49)

1. Aliberti JC, Machado FS, Souto JT, Campanelli AP, Teixeira MM, Gazzinelli RT, Silva JS 1999. Beta-chemokines enhance parasite uptake and promote nitric oxide-dependent microbiostatic activity in murine inflammatory macrophages infected with Trypanosoma cruzi. Infect Immun 67: 4819-4826.
2. Andrade ZA 1983. Mechanisms of myocardial damage in Trypanosoma cruzi infection. Ciba Found Symp 99: 214-233.
3. Brener Z, Gazzinelli RT 1997. Immunological control of Trypanosoma cruzi infection and pathogenesis of Chagas' disease. Int Arch Allergy Immunol 114: 103-110.
4. Botoni FA, Poole-Wilson PA, Ribeiro AL, Okonko DO, Oliveira BM, Pinto AS, Teixeira MM, Teixeira AL Jr, Reis AM, Dantas JB, Ferreira CS, Tavares WC Jr, Rocha MO 2007. A randomized trial of carvedilol after renin-angiotensin system inhibition in chronic Chagas cardiomyopathy. Am Heart J 153: e1-8.
5. Bu DX, Griffin G, Lichtman AH 2011. Mechanisms for the anti-inflammatory effects of statins. Curr Opin Lipidol 22: 165-170.
6. Caldas IS, Talvani A, Caldas S, Carneiro CM, de Lana M, da Matta Guedes PM, Bahia MT, 2008. Benznidazole therapy during acute phase of Chagas disease reduces parasite load but does not prevent chronic cardiac lesions. Parasitol Res 103: 413-421.
7. Cheng X, Liao YH, Zhang J, Li B, Ge H, Yuan J, Wang M, Lu B, Liu Y, Cheng Y 2005. Effects of atorvastatin on Th polorization in patients with acute myocardial infarction. The Europ J Heart Failure 7: 1099-1104.
8. Coelho dos Santos JS, Menezes CA, Villani FN, Magalhães LM, Scharfstein J, Gollob KJ, Dutra WO 2010. Captopril increases the intensity of monocyte infection by Trypanosoma cruzi and induces human T helper type 17 cells. Clin Exp Immunol 163: 528-536.
9. Cui X, Chopp M, Zacharek A, Roberts C, Lu M, Savant-Bhonsale S, Chen J 2009. Chemokine, vascular and therapeutic effects of combination simvastatin and BMSC treatment of stroke. Neurobiol Dis 36: 35-41.
10. Devaraj S, Rogers J, Jialal I 2007. Statins and biomarkers of inflammation. Curr Atheroscler Rep 9: 33-41.
11. Elrod JW, Lefer DJ 2005. The effects of statins on endothelium, inflammation and cardioprotection. Drug News Perspect 18: 229-236.
12. Florin-Christensen M, Florin-Christensen J, Garin C, Isola E, Brenner RR, Rasmussen L 1990. Inhibition of Trypanosoma cruzi growth and sterol biosynthesis by lovastatin. Biochem Biophys Res Commun 166: 1441-1445.
13. Greer JJ, Kakkar AK, Elrod JW, Watson LJ, Jones SP, Lefer DJ 2006. Low-dose simvastatin improves survival and ventricular function via e-NOS in congestive heart failure. Am J Physiol Heart Circ Physiol 291: H2743-H2751.
14. Guedes PM, Veloso VM, Talvani A, Diniz LF, Caldas IS, Do-Valle- Matta MA, Santiago-Silva J, Chiari E, Galvão LM, Silva JS, Bahia MT 2010. Increased type 1 chemokine expression in experimental Chagas disease correlates with cardiac pathology in beagle dogs. Vet Immunol Immunopathol 138: 106-113.
15. Hankins EG, Gillespie JR, Aikenhead K, Buckner FS 2005. Upregulation of sterol C14-demethylase expression in Trypanosoma cruzi treated with sterol biosynthesis inhibitors. Mol Biochem Parasitol 144: 68-75.
16. Haraguchi FK, Pedrosa ML, Paula H, Santos RC, Silva ME 2010. Evaluation of biological and biochemical quality of whey protein. J Med Food 13: 1505-1509.
17. Hardison JL, Wrightsman RA, Carpenter PM, Kuziel WA, Lane TE, Manning JE 2006. The CC chemokine receptor 5 is important in control of parasite eplication and acute cardiac inflammation following infection with Trypanosoma cruzi. Infect Immun 74: 135-143.
18. Hurtado-Guerrrero R, Pena-Dias J, Montalvetti A, Ruiz-Perez LM, Gonzalez-Pacanowska D, 2002. Kinetic properties and inhibition of Trypanosoma cruzi 3-hydroxy-3-methylglutaryl CoA reductase. FEBS Letters 510: 141-144.
19. Lannes-Vieira J, Silverio JC, Pereira IR, Vinagre NF, Carvalho CME, Paiva CN, Silva AA 2009. Chronic Trypanosoma cruzi-elicited cardiomyopathy: from the discovery to the proposal of rational therapeutic interventions targeting cell adhesion molecules and chemokines receptors - how to make a dream come true. Mem Inst Oswaldo Cruz 104 (Suppl. I): 226-235.
20. Leon JS, Wang K, Engman DM 2003. Captopril ameliorates myocarditis in acute experimental Chagas disease. Circulation 107: 2264-2269.
21. Liao JK 2002. Isoprenoids as mediators of the biological effects of statins. J Clin Invest 109: 1594-1602.
22. Lin Y, Ye S, Chen Y, Li X, Yang GW, Fan A, Wang Y 2009. The effect of simvastatin on the serum monocyte chemoattractant protein-1 and intracellular adhesion molecule-1 levels in diabetic rats. J Diab Complications 23: 214-218.
23. Lula JF, Rocha MO, Nunes M do C, Ribeiro AL, Teixeira MM, Bahia MT, Talvani A 2009. Plasma concentrations of tumour necrosis factor-alpha, tumour necrosis factor-related apoptosis-inducing ligand, and FasLigand/CD95L in patients with Chagas cardiomyopathy correlate with left ventricular dysfunction. Eur J Heart Fail 11: 825-831.
24. Machado FS, Koyama NS, Carregaro V, Ferreira BR, Milanezi CM, Teixeira MM, Rossi MA, Silva JS 2005. CCR5 plays a critical role in the development of myocarditis and host protection in mice infected with Trypanosoma cruzi. J Infect Dis 191: 627-636.
25. Marino AP, da Silva A, dos Santos P, Pinto LM, Gazzinelli RT, Teixeira MM, Lannes-Vieira J 2004. Regulated on activation, normal T cell expressed and secreted (RANTES) antagonist (MetRANTES) controls the early phase of Trypanosoma cruzi-elicited myocarditis. Circulation 110: 1443-1449.
26. Medeiros GA, Silverio JC, Marino AP, Roffe E, Vieira V, Kroll-Palhares K, Carvalho CE, Silva AA, Teixeira MM, Lannes-Vieira J 2009. Treatment of chronically Trypanosoma cruzi-infected mice with a CCR-1/CCR5 antagonist (Met-RANTES) results in amelioration of cardiac tissue damage. Microbes Infect 11: 264-273.
27. Melo L, Caldas IS, Azevedo MA, Gonçalves KR, Nascimento AFS, Figueiredo VP, Diniz LF, Lima WG, Torres RM, Bahia MT, Talvani A 2011. Low doses of simvastatin therapy ameliorate cardiac inflammatory remodeling in Trypanosoma cruzi-infected dogs. Am J Trop Med Hyg 84: 325-331.
28. Mizuno Y, Jacob RF, Mason RP 2011. Inflammation and the development of atherosclerosis: effects of lipid-lowering therapy. J Atheroscler Thromb 18: 351-358.
29. Morris SA, Weiss LM, Factor SM, Bilezikian JP, Tanowitz H, Wittner M 1989. Verapamil ameliorates clinical, pathological and biochemical manifestations of experimental chagasic cardiomyopathy in mice. J Am Coll Cardiol 14: 782-789.
30. +) T lymphocytes in vitro and preferentially decrease infection of R5 versus X4 HIV-1. Plos ONE 23: e-470
31. K, Fujita M, Kitakaze M, Hori M, Liao JK 2003. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 19: 839-843.
32. Paiva CN, Figueiredo RT, Kroll-C, Gibaldi D, Pyrrho Ados S, Benjamim CF, Lannes-Vieira J, Bozza MT 2009. CCL2/MCP-1 controls parasite burden, cell infiltration and mononuclear activation during acute Trypanosoma cruzi infection. J Leukoc Biol 86: 1239-1246.
33. Paula-Costa G, Silva RR, Pedrosa MC, Pinho V, de Lima WG, Teixeira MM, Bahia MT, Talvani A 2010. Enalapril prevents cardiac immune-mediated damage and exerts anti-Trypanosoma cruzi activity during acute phase of experimental Chagas disease. Parasite Immunol 32: 202-208.
34. Prata A 2001. Clinical and epidemiological aspects of Chagas disease. Lancet Infect Dis 1: 92-100.
35. Priotto S, Sartori MJ, Repossi G, Valentich MA 2009. Trypanosona cruzi: participation of cholesterol and placental alkaline phosphatase in the host cell invasion. Exp Parasitol 122: 70-73.
36. Quist-Paulsen P 2010. Statins and inflammation: an update. Curr Opin Cardiol 25: 399-405.
37. + lymphocytes. Am J Trop Med Hyg 48: 637-644.
38. Sánchez-Guillén MC, Bernabé C, Tibayrenc M, Zavala-Castro J, Totolhua JL, Méndez-Lopes J, González-Mejia ME, Torres-Rasgado E, Lópes-Colombo A, Pérez-Fuentes R 2006. Trypanosoma cruzi strains isolated from human, vector and animals reservoir in the same endemic region in Mexico and typed as T. cruzi I, discrete typing unit 1, exhibit considerable biological diversity. Mem Inst Oswaldo Cruz 101: 585-590.
39. Santos DM, Martins TA, Caldas IS, Diniz LF, Machado-Coelho GL, Carneiro CM, Oliveira R de P, Talvani A, Lana M, Bahia MT 2009. Benznidazole alters the pattern of cyclophosphamide-induced reactivation in experimental Trypanosoma cruzi-dependent lineage infection. Acta Trop 113: 134-138.
40. Serrano CV Jr, Yoshida VM, Venturinelli ML, D'Amico E, Monteiro HP, Ramires JA, da Luz PL 2001. Effect of simvastatin on monocyte adhesion molecule expression in patients with hypercholesterolemia. Atherosclerosis 157: 505-512.
41. Talvani A, Ribeiro CS, Aliberti JC, Michailowsky V, Santos PV, Murta SM, Romanha AJ, Almeida IC, Farber J, Lannes-Vieira J, Silva JS, Gazzinelli RT 2000. Kinetics of cytokine gene expression in experimental chagasic cardiomyopathy: tissue parasitism and endogenous IFN-gamma as important determinants of chemokine mRNA expression during infection with Trypanosoma cruzi. Microbes Infect 2: 851-866.
42. Talvani A, Teixeira MM 2011. Inflammation and Chagas disease: some mechanisms and relevance. Adv Parasitology 76: 171-194
43. Teixeira MM, Gazzinelli RT, Silva JS 2002. Chemokines, inflammation and Trypanosoma cruzi infection. Trends Parasitol 18: 262-265.
44. Tsuchiya A, Nagotani S, Hayashi T, Deguchi K, Sehara Y, Yamashita T, Zhang H, Lukic V, Kamiya T, Abe K 2007. Macrophage infiltration, lectin-like oxidized-LDL receptors-1 and monocyte chemoattractant protein-1 are reduced by chronic HMG-CoA reductase inhibition. Curr Neurovasc Res 4: 268-273.
45. Urbina JA 2009. Ergosterol biosynthesis and drug development for Chagas disease. Mem Inst Oswaldo Cruz 104 (Suppl.I): 311-318.
46. Urbina JA, Lazardi K, Marchan E, Visbal G, Aguirre T, Piras MM, Piras R, Maldonado RA, Payares G, de Souza W 1993. Mevinolin (lovastatin) potentiates the antiproliferative effects of ketoconazole and terbinafine against Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies. Antimicrob Agents Chemother 37: 580-591.
47. WHO - World Health Organization 2010. Chagas disease (American trypanosomiasis). Fact sheet 340. Available from: who.int/mediacentre/factsheets/fs340/.
48. Yin R, Zhu J, Shao H, Cheng X, Feng X, Li Z, Jing H 2007. Inhibition of chemokine receptor CCR2 and CCR5 expression contributes to simvastatin-induced attenuation of cardiac allograft vasculopathy. J Heart Lung Transplant 26: 485-493.
49. Zingales B, Andrade SG, Briones MRS, Campbell DA, Chiari E, Fernandes O, Guhl F, Lages-Silva E, Macedo AM, Machado CR, Miles MA, Romanha AJ, Sturm NR, Tibayrenc M, Schijman AG 2009. A new consensus for Trypanosoma cruzi intraspecific nomenclature: second revision meeting recommends TcI to TcVI. Mem Inst Oswaldo Cruz 104: 1051-1054.